Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN® Treatment Under Condition of Actual Usage in Clinical Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01212601

Enrollment

203

Registered

2010-09-30

Start date

2011-01-31

Completion date

2012-11-30

Last updated

2012-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

S. Aureus Bloodstream Infection

Keywords

safety, efficacy, Chinese patients, practice

Brief summary

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Detailed description

MC MD

Interventions

None listed

Study design

Observational model

COHORT

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient has received CUBICIN treatment, decided by treating physician * A patient who is considered as ethnic Chinese * Provision of subject informed consent

Exclusion criteria

* A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

Design outcomes

Primary

Measure	Time frame
AEs of CUBICIN therapy	2 weeks
clinical response of CUBICIN therapy at each available time point	2 weeks

Secondary

Measure	Time frame
CPK level monitoring and results	2 weeks
treatment duration	2 weeks
Time to clinical response	2 weeks

Countries

China

Outcome results